SBIO and BBP, both of which debuted in December, are up an average of 38% this year. BBC recently increased its lineup to 39 from 33 stocks. BBP tracks the BioShares Biotechnology Products Index, which is also sponsored by LifeSci Index Partners. That index follows U.S.-listed biotech companies with a primary product offering or product candidate that has landed FDA approval. [New Breed Biotech ETFs]
SBIO which focuses on small- and mid-cap companies that have one or more drugs in either Phase II or Phase III U.S. FDA clinical trials. Investors have allocated $13.7 million to the ETF this month. While that may not sound like much relative to the inflows to older biotech ETFs, remember that SBIO is not yet six months old and $13.7 million represents about 15% of the ETF’s assets under management tally.
SPDR S&P Biotech ETF
